Lupin turns highly volatile after announcing Q1 earnings

Lupin was down 0.7% to Rs 1,680.25 at 13:39 IST on BSE, amid intraday volatility after consolidated net profit rose 55.12% to Rs 881.95 crore on 39.92% growth in total income to Rs 4522.02 crore in Q1 June 2016 over Q1 June 2015.

The result was announced during market hours today, 9 August 2016.

Meanwhile, the S&P BSE Sensex was down 148.70 points or 0.53% at 28,033.87.

On BSE, so far 3.06 lakh shares were traded in the counter as against average daily volume of 1.22 lakh shares in the past one quarter. The stock was highly volatile. The stock lost as much as 1.92% at the day's low of Rs 1,660.10 so far during the day. The stock rose as much as 2.17% at the day's high of Rs 1,729.50 so far during the day. The stock had hit a record high of Rs 2,127 on 6 October 2015. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had underperformed the market over the past one month till 8 August 2016, advancing 3.39% compared with 3.89% rise in the Sensex. The scrip had also underperformed the market in past one quarter, gaining 6.69% as against Sensex's 11.71% rise.

The large-cap company has equity capital of Rs 90.20 crore. Face value per share is Rs 2.

Lupin is a pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB segment.

Powered by Capital Market - Live News